Medications for Mastocytosis Systemic
9 results
Ayvakit (avapritinib)
(avapritinib)Blueprint Medicines Corporation
Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM), with limitations regarding platelet counts below 50 × 10⁹/L.
Imatinib mesylate (imatinib mesylate)
(IMATINIB MESYLATE)Camber Pharmaceuticals, Inc.
Usage: This drug is indicated for treating newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)BluePoint Laboratories
Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Archis Pharma LLC
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Qilu Pharmaceutical Co., Ltd.
Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Wockhardt USA LLC.
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in blast crisis or after interferon failure, adult relapsed/refractory Philadelphia positive acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases with PDGFR rearrangements, aggressive systemic mastocytosis without D816V c-Kit mutation, hypereosinophilic syndrome, and unresectable dermatofibrosarcoma protuberans.
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)American Health Packaging
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML in various phases post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) in adults, and newly diagnosed Ph+ ALL in pediatric patients, among other specific malignancies.
Imatinib mesylate (imatinib)
(imatinib)Mylan Pharmaceuticals Inc.
Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
Rydapt (rydapt)
(RYDAPT)Novartis Pharmaceuticals Corporation
Usage: RYDAPT is indicated for the treatment of adult patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) in combination with chemotherapy, and for aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).